Awards

Introducing the Pharmaceutical Technology Excellence Awards 2024

The 2024 Pharmaceutical Technology Excellence Awards are open for submissions. Download our Research Guide for more details.

The Pharmaceutical Technology Excellence Awards celebrate the greatest achievements and innovations in the industry. The programme provides a platform to recognize the people and companies that are driving change.

Our programme is designed to highlight excellence within the sector assessing a variety of corporate activities including deals, business projects and company initiatives – both internal and within the community.

How to take part in the Excellence Awards

To learn how to enter your organisation for the awards, please download the Research Guide. This comprehensive guide provides details on the necessary submission information, and the process for submitting information to us.

Download our Research Guide for more information

How the Excellence Awards work

Companies and institutions undergo evaluation based on their performance in 12 key Areas of Excellence, supported by evidence from both our research and ranking submission process.

  • Business Expansion
  • Diversity
  • Environmental
  • Financing
  • Innovation
  • Investments
  • M&A
  • Marketing
  • Product Launches
  • Research and Development
  • Safety
  • Social

For comprehensive details on our methodology and scoring system, please download the Research Guide.

Making the most of your award win

Participating in the Excellence Awards offers your company numerous benefits, including the ability to showcase your achievements to the market and attract new prospective clients.

For a comprehensive understanding of the benefits, the scale of our audience, and the marketing packages available, please download the Research Guide or contact Tina Ross at tina.ross@globaldata.com.

Frequently-Asked-Questions (FAQ)

Are there any associated costs with the awards?
While there is no fee for submitting information, we offer a variety of packages to enhance your exposure and promote your success to our audience. For details, please contact Tina Ross at tina.ross@globaldata.com.

What sort of projects can I submit as case studies?
Ensure that case studies align with one of our 12 Areas of Excellence. Refer to the examples provided under each category in the following section for guidance.

I’d like to submit a case study, but I’m unsure about the appropriate category for submission
Submission for a specific category is not mandatory; we will consider relevant case studies for all applicable categories.

How will our case study be used?
Case study details may be published with your ranking. If there are specific details you prefer not to be disclosed, please clearly state this in the description.

I would like to submit a long-term project as a case study. Is it eligible for consideration in this year’s research?
The project will be considered valid if a substantial amount of work has been undertaken during the research period.

Can I get an extension to the submission deadline?
​​​​​​​
Kindly email your extension request along with the desired duration to our research team.

Contact Us

For more information on the awards and our methodology, please contact Tina Ross at tina.ross@globaldata.com.

Go to article: Home | Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: Syngene Company InsightGo to article: SyngeneGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: PCI Pharma ServicesGo to article: AlfatestLAB - CPHIGo to article: RHEACELL Company InsightGo to article: In DepthGo to article: Cell and gene therapy approvals drive paradigm change in manufacturingGo to article: After the Lykos debacle, what’s next for psychedelic therapies?Go to article: Compounding pharmacies caught in counterfeit controversyGo to article: How the Covid-19 pandemic will help researchers with the mpox emergencyGo to article: Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship effortsGo to article: Clinical research in the UK must build on industry collaboration, says NIHR directorGo to article: Keytruda and Opdivo: a decade reviewGo to article: Alphial - CPHIGo to article: RephineGo to article: Rephine - CPHIGo to article: Thematic Take: AIGo to article: Thematic Take: contentsGo to article: Foreword: Generative AI as a force of creative destructionGo to article: The road to advanced AI capabilitiesGo to article: AI technology: Market size and growth forecasts Go to article: Timeline: a history of AIGo to article: The impact of AI on the pharma sectorGo to article: Case studies: AI in pharmaGo to article: Latest news: AI in pharmaGo to article: AI boom set to revolutionise healthcare in EuropeGo to article: How NVIDIA grew with the healthcare market instead of pushing into itGo to article: Capturing the genAI boom for drug developmentGo to article: New AI model boosts early osteoporosis diagnosis for ageing populationsGo to article: Impact of AI on metabolic disorder clinical trialsGo to article: Resist temptation to rapidly roll out AI – executives must focus on talent and trainingGo to article: Is AI really helping employees?Go to article: Is your business ready for the rise of AI agents?Go to article: Deal activity related to AI in the pharma industry since 2021Go to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: Techniconsult Firenze - CPHIGo to article: Science4TechGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue